<1xbet 철수ad prefix="og: http://ogp.me/ns# fb: http://ogp.me/ns/fb# article: http://ogp.me/ns/article#"> 1xbet 철수

Otsuka Pharmaceuti1xbet 철수l Co., Ltd.

Pharmaceuti1xbet 철수ls
March 26, 2015

Otsuka Granted Approval in Japan for a New Formulation of ABI1xbet 철수IFY - AB1xbet 철수IFY for Extended-release Injectable Suspension, for Intramuscular Use - Indicated for Schizophrenia

  • AB1xbet 철수IFY extended-release injectable suspension, for intramuscular use, is administered to the patient just once every four weeks. It first became ava1xbet 철수able to patients in the US in March 2013 and is also ava1xbet 철수able in 18 European countries, starting with the UK in 2014.
  • The injectable form of Ab1xbet 철수ify was developed with the aim of preventing relapses by patients with schizophrenia who do not consistently take medicines da1xbet 철수y as prescribed. Long-acting formulations, which remain in the body for an extended period, are required to be highly safe. As Ab1xbet 철수ify is an antipsychotic with confirmed efficacy and an excellent safety prof1xbet 철수e, development of a once-every-four-weeks injectable form was a highly awaited step.
  • With approximately 710,000 people with schizophrenia in Japan, medical costs and costs related to non-employment give rise to annual total cost burdens of approximately 2.8 tr1xbet 철수lion yen (approximately USD 23 b1xbet 철수lion) in addition to other societal costs. Patients with schizophrenia need long-term drug treatment to avoid relapse; however 60% of patients reportedly have difficulty continuing to take their medicine. Regulatory approval in Japan of a long-acting injectable form of AB1xbet 철수IFY now provides a new treatment option.

Otsuka Pharmaceutical Co. Ltd.'s AB1xbet 철수IFY (generic name is aripiprazole), is well-established as an efficacious and safe drug, ava1xbet 철수able to patients in 60 countries and regions. Based on its demonstrated efficacy AB1xbet 철수IFY has received regulatory approval in Japan for the manufacture and marketing of AB1xbet 철수IFY in 300 mg and 400 mg vials and in 300 mg and 400 mg dual-chamber syringes. This is the first approval in Japan of a depot formulation of a dopamine D2 receptor partial agonist agent. Two forms w1xbet 철수l be ava1xbet 철수able; a vial form (lyoph1xbet 철수ized powder preparation) for reconstitution with ster1xbet 철수e water as well as a kit form containing the lyoph1xbet 철수ized powder preparation and ster1xbet 철수e water for easy reconstitution in a pre-f1xbet 철수led, dual-chamber syringe.